Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 28% Improvement Relative Risk Discharge 15% Wargny et al. NCT04324736 CORONADO Metformin Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? Retrospective 2,794 patients in France (March - April 2020) Lower mortality (p=0.026) and higher discharge (p=0.019) Wargny et al., Diabetologia, doi:10.1007/s00125-020-05351-w Favors metformin Favors control
Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study
Wargny et al., Diabetologia, doi:10.1007/s00125-020-05351-w, CORONADO, NCT04324736 (history)
Wargny et al., Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from.., Diabetologia, doi:10.1007/s00125-020-05351-w, CORONADO, NCT04324736
Feb 2021   Source   PDF  
  All Studies   Meta
Retrospective 2,796 hospitalized diabetes patients with COVID-19 in France, showing lower mortality with metformin use.
risk of death, 28.3% lower, RR 0.72, p = 0.03, treatment 247 of 1,553 (15.9%), control 330 of 1,241 (26.6%), NNT 9.4, adjusted per study, odds ratio converted to relative risk, multivariable, day 28.
risk of no hospital discharge, 14.8% lower, RR 0.85, p = 0.02, treatment 690 of 1,553 (44.4%), control 702 of 1,241 (56.6%), NNT 8.2, adjusted per study, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, multivariable, day 28.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wargny et al., 17 Feb 2021, retrospective, France, peer-reviewed, 43 authors, study period 10 March, 2020 - 10 April, 2020, trial NCT04324736 (history) (CORONADO).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Abstract: Diabetologia (2021) 64:778–794 ARTICLE Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study Matthieu Wargny 1,2 & Louis Potier 3,4 & Pierre Gourdy 5,6 & Matthieu Pichelin 1 & Coralie Amadou 7,8 & Pierre-Yves Benhamou 9,10 & Jean-Baptiste Bonnet 11 & Lyse Bordier 12 & Olivier Bourron 13,14,15,16 & Claude Chaumeil 17 & Nicolas Chevalier 18 & Patrice Darmon 19,20 & Blandine Delenne 21 & Delphine Demarsy 22 & Marie Dumas 23 & Olivier Dupuy 24 & Anna Flaus-Furmaniuk 25 & Jean-François Gautier 4,26 & Anne-Marie Guedj 27 & Nathalie Jeandidier 28 & Etienne Larger 29 & Jean-Philippe Le Berre 30 & Myriam Lungo 31 & Nathanaëlle Montanier 32 & Philippe Moulin 33 & Françoise Plat 34 & Vincent Rigalleau 35 & René Robert 36 & Dominique Seret-Bégué 37 & Pierre Sérusclat 38 & Sarra Smati 1 & Jean-François Thébaut 17 & Blandine Tramunt 5,6 & Camille Vatier 39,40 & Fritz-Line Velayoudom 41 & Bruno Vergès 42 & Patrice Winiszewski 43 & Audrey Zabulon 44 & Pierre-Antoine Gourraud 2 & Ronan Roussel 3,4 & Bertrand Cariou 1 & Samy Hadjadj 1 & for the CORONADO investigators Received: 2 September 2020 / Accepted: 10 November 2020 / Published online: 17 February 2021 # The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature 2021 Abstract Aims/hypothesis This is an update of the results from the previous report of the CORONADO (Coronavirus SARS-CoV-2 and Diabetes Outcomes) study, which aims to describe the outcomes and prognostic factors in patients with diabetes hospitalised for coronavirus disease-2019 (COVID-19). Methods The CORONADO initiative is a French nationwide multicentre study of patients with diabetes hospitalised for COVID-19 with a 28-day follow-up. The patients were screened after hospital admission from 10 March to 10 April 2020. We mainly focused on hospital discharge and death within 28 days. Results We included 2796 participants: 63.7% men, mean age 69.7 ± 13.2 years, median BMI (25th–75th percentile) 28.4 (25.0–32.4) kg/m2. Microvascular and macrovascular diabetic complications were found in 44.2% and 38.6% of participants, respectively. Within 28 days, 1404 (50.2%; 95% CI 48.3%, 52.1%) were discharged from hospital with a median duration of hospital stay of 9 (5–14) days, while 577 participants died (20.6%; 95% CI 19.2%, 22.2%). In multivariable models, younger age, routine metformin therapy and longer symptom duration on admission were positively associated with discharge. History of microvascular complications, anticoagulant routine therapy, dyspnoea on admission, and higher aspartate aminotransferase, white cell count and C-reactive protein levels were associated with a reduced chance of discharge. Factors associated with death within 28 days mirrored those associated with discharge, and also included routine treatment by insulin and statin as deleterious factors. Conclusions/interpretation In patients with diabetes hospitalised for COVID-19, we established prognostic factors for hospital discharge and death that could help clinicians in this pandemic period. Trial registration identifier: NCT04324736 Keywords Admission plasma glucose . COVID-19 . Death . Diabetes . Discharge . HbA1c . Home discharge . Mechanical ventilation Matthieu Wargny and Louis Potier contributed equally to the manuscript and must be considered as joint first authors. Bertrand Cariou and..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop